Business Segments · Research and development expenses
Business Segments — Research and development expenses
Pfizer Business Segments — Research and development expenses increased by 10.1% to $2.14B in Q1 2026 compared to the prior quarter.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026
How to read this metric
Higher spending indicates a commitment to innovation, though it must be balanced against the probability of clinical success.
Detailed definition
Expenditures dedicated to the discovery, clinical testing, and regulatory approval of new pharmaceutical products within...
Peer comparison
A primary metric for evaluating the innovation intensity of pharmaceutical companies.
Metric ID:
pfe_segment_biopharma_research_and_development_expensesHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $1.94B | $2.14B |
| QoQ Change | — | +10.1% |
| YoY Change | — | +10.1% |
Range$1.94B – $2.14B
Avg YoY Growth+10.1%
Median YoY Growth+10.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's business segments — research and development expenses?
- Pfizer (PFE) reported business segments — research and development expenses of $2.14B in Q1 2026.
- What does business segments — research and development expenses mean?
- The amount spent on discovering and developing new drugs within the biopharma segment.